279261-83-5

Basic information

• Product Name: 4-(4-BROMO-3-FLUOROPHENYL)MORPHOLINE
• Synonyms: 4-(4-BROMO-3-FLUOROPHENYL)MORPHOLINE
• CAS NO: 279261-83-5
• Molecular Formula: C₁₀H₁₁BrFNO
• Molecular Weight: 260.1
• Product Categories: MIscellaneous Reagents
• Mol File: 279261-83-5.mol

Chemical Properties

• Boiling Point: 351.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.502±0.06 g/cm3(Predicted)
• PKA: 3.26±0.40(Predicted)
• CAS DataBase Reference: 4-(4-BROMO-3-FLUOROPHENYL)MORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMO-3-FLUOROPHENYL)MORPHOLINE(279261-83-5)
• EPA Substance Registry System: 4-(4-BROMO-3-FLUOROPHENYL)MORPHOLINE(279261-83-5)

Safety Data

• Hazardous Substances Data: 279261-83-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-BROMO-3-FLUOROPHENYL)MORPHOLINE is used as an intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting vascular adhesion proteins. Its unique structure allows it to interact with specific biological targets, making it a valuable component in the development of new drugs for treating conditions related to vascular adhesion.
Used in the Preparation of Vascular Adhesion Protein Inhibitors:
4-(4-BROMO-3-FLUOROPHENYL)MORPHOLINE is used as a key component in the development of vascular adhesion protein inhibitors. These inhibitors play a crucial role in modulating the immune response and preventing the adhesion of leukocytes to the vascular endothelium, which is a critical step in the pathogenesis of various inflammatory and autoimmune diseases. By incorporating this compound into the molecular structure of inhibitors, researchers can potentially develop more effective and targeted therapies for these conditions.

Upstream product

• 367-24-8 4-bromo-2-fluoroaniline 
• 75-36-5 acetyl chloride 
• 111-44-4 3-oxa-1,5-dichloropentane 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 656-65-5 3-fluoro-4-bromophenylamine 

Relevant articles and documents

TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES

The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

Anilide derivative, production and use thereof

This invention is to provide a compound of the formula: wherein R1is an optionally substituted 5- to 6-membered ring; the ring A is an optionally substituted 6- to 7-membered ring; the ring B is an optionally substituted benzene ring; n is an integer of 1 or 2; Z is a chemical bond or a divalent group; R2is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, (2) an optionally substituted nitrogen-containing heterocyclic ring group which may contain a sulfur atom or an oxygen atom as ring constituting atoms and wherein a nitrogen atom may form a quaternary ammonium, (3) a group binding through a sulfur atom or (4) a group of the formula: ?wherein k is 0 or 1, and when k is 0, a phosphorus atom may form a phosphonium; and R5and R6are independently an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted amino group, and R5and R6may bind to each other to form a cyclic group together with the adjacent phosphorus atom, or a salt thereof , which is useful for antagonizing CCR5 and also for the prevention and treatment of infectious disease of HIV.